NCT00287742View on ClinicalTrials.gov

A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease

PHASE3TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2002

Study Completion Date

March 31, 2003

Conditions
Alzheimer's DiseaseDementia
Interventions
DRUG

risperidone

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT00287742 - A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease | Biotech Hunter | Biotech Hunter